Myriad Genetics is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. At the end of fiscal year 2015, Myriad had annual revenue of approximately $723.1 million and 2,038 employees,
Myriad is the global leader and pioneer in the molecular diagnostics field with twelve innovative diagnostic products. Through our proprietary technologies, we believe we are positioned to identify important disease genes, the proteins they produce, and the biological pathways in which they are involved to better understand the genetic basis of human disease and the role that genes and their related proteins may play in the disease process.